Market research
471A.F aTyr Pharma, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 19.33
- Dividend yield
- Not available
- Beta
- 0.53
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0021202025
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 19.33
- Dividend yield
- Not available
- Beta
- 0.53
About
About aTyr Pharma, Inc
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment of other ILDs, such as chronic hypersensitivity pneumonitis (CHP) and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 471A.F discussion.
5 years, 5 months ago
aTyr Pharma, Inc is currently in a long term uptrend where the price is trading 9.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.8.
aTyr Pharma, Inc's total revenue rose by 1325.7% to $2M since the same quarter in the previous year.
Its net income has increased by 17.4% to $-5M since the same quarter in the previous year.
Finally, its free cash flow fell by 9.1% to $-5M since the same quarter in the previous year.
Based on the above factors, aTyr Pharma, Inc gets an overall score of 4/5.